A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
Public ClinicalTrials.gov record NCT04497987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.
Study identification
- NCT ID
- NCT04497987
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,180 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2, 2020 (Actual)
- Primary completion
- Jan 16, 2021 (Actual)
- Completion
- May 20, 2021 (Actual)
- Last update posted
- Feb 4, 2022
2020 – 2021
United States locations
- U.S. sites
- 27
- U.S. states
- 23
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Unv of AL Sch of Med Div of Infectious Diseases | Birmingham | Alabama | 35294 | — |
| Care Access Research | Phoenix | Arizona | 85023 | — |
| Allergy and Asthma Clin of NW Ark | Bentonville | Arkansas | 72712 | — |
| Care Access Research LLC | Huntington Beach | California | 92648 | — |
| Alta Bates SMC | Oakland | California | 94609 | — |
| University of Colorado-Anschultz Medical Campus | Aurora | Colorado | 80045 | — |
| NIAID | Miami | Florida | 33136 | — |
| NIAID | Decatur | Georgia | 30030 | — |
| Belmont Village Lincoln Park | Lincoln Park | Illinois | 60614 | — |
| Family Medicine | Indianapolis | Indiana | 46260 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Care Access Rch Lake Charles | Lake Charles | Louisiana | 70601 | — |
| Tulane University School of Medicine | New Orleans | Louisiana | 70112 2715 | — |
| NIAID - National Institute of Allergy & Infectious Diseases | Bethesda | Maryland | 20892 | — |
| Care Access | Boston | Massachusetts | 02110 | — |
| St. Paul IDA-CARe | Saint Paul | Minnesota | 55101 | — |
| Care Access | Jackson | Mississippi | 39206 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Children's Hospital & Medical Center | Omaha | Nebraska | 68114 | — |
| Care Access Research - Bronx | The Bronx | New York | 10456 | — |
| NIAD | Chapel Hill | North Carolina | 27599 | — |
| Valley Medical Primary Care | Centerville | Ohio | 45459 | — |
| Univ of Cin College of Med | Cincinnati | Ohio | 45219 | — |
| OSU Med Intl Med Houston Ctr | Tulsa | Oklahoma | 74127 | — |
| Donahoe Manor | Bedford | Pennsylvania | 15522 | — |
| Belmont Village, West Univ | Houston | Texas | 77025 | — |
| Burke Internal Medicine and Research | Burke | Virginia | 22015 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04497987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2022 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04497987 live on ClinicalTrials.gov.